Heron Therapeutics, Inc.
$945.0K 4,695 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
OrganOx Ltd
OrganOx Ltd reported $944,603.27 across General Payments, Research, and Ownership to 100 physicians and teaching hospitals across 155 transactions.
- $944.6K Above-median payer
- All-tracks total
- 155 Below-median volume
- Transactions
- 100 Below-median reach
- Recipients
- +$215.0K
- General Payments vs PY2023
OrganOx Ltd reported $944,603.27 across all CMS Open Payments tracks (General + Research + Ownership) to 100 physicians and teaching hospitals in Program Year 2024 - ranking #630 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $271,037.76, averaging $9.4K per recipient.
How OrganOx Ltd's $944.6K all-tracks total breaks down
OrganOx Ltd's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
33/100
Total payments
F
19/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer organox-ltd OrganOx Ltd
$944.6K · #630/1,925 · 0.0% industry · PY2024
- TOT $944.6K
- RANK #630
- SHARE 0.0%
- TXN 155
- RCP 100
- CAT 7
- GEN $271.0K
- ΔGEN +$215.0K
- TOP1 55.3%
- PY 2024
Volume peers
Nearest volume peer: Heron Therapeutics, Inc. ($945.0K)
OrganOx Ltd sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
OrganOx Ltd's CMS-reported General Payments increased by $215.0K (+383.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ORGANOX LTDPY2023: ORGANOX LTDPY2024: OrganOx Ltd. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $56,047.63
- PY2024
- $271,037.76
What the Data Shows for OrganOx Ltd
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For OrganOx Ltd, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Grant" leads the 7-category general-payment breakdown below at $150.0K (55.3% of General Payments, 1 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 7 types of general payments, OrganOx Ltd's largest category was "Grant" at $150.0K - 55.3% of General Payments.
OrganOx Ltd reports 7 general-payment categories - the top three are Grant (55.3%), Compensation for Services Other Than Consulting (26.1%), and Consulting Fee (8.9%). The remaining 4 categories make up 9.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How OrganOx Ltd divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Grant | $150.0K | 1 | 55.3% |
| Compensation for Services Other Than Consulting | $70.7K | 28 | 26.1% |
| Consulting Fee | $24.2K | 8 | 8.9% |
| Travel and Lodging | $19.0K | 20 | 7.0% |
| Honoraria | $4.5K | 1 | 1.7% |
| Food and Beverage | $2.4K | 41 | 0.9% |
| Gift | $182.95 | 1 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $222,683.11 (82.2%) of $271,037.76 in this company's General Payments records across 50 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for OrganOx Ltd
The five named recipients with the highest reported General Payments from this company
- 1
Cleveland Clinic Hospital
$150,000.00 across 1 reported transactions
- 2
Anthony Dalessandro
$37,798.01 across 15 reported transactions
- 3
David Nasrallah
$13,000.00 across 2 reported transactions
- 4
Kim Olthoff
$11,102.84 across 5 reported transactions
- 5
Elizabeth Pomfret
$10,782.26 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
OrganOx Ltd's spend rank (#630 of 1,925, top 33% by spend) and concentration rank (#526 of 1,838, top 29% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Seres Therapeutics, Inc. : $132.4K total payments, HHI 3375
- Orthopedic Sciences, Inc. : $4.0K total payments, HHI 3369
- L&k Biomed Co. , Ltd. : $864.8K total payments, HHI 3358
- Nidek Incorporated : $16.8K total payments, HHI 3356
- Grifols Diagnostic Solutions, Inc. : $48.20 total payments, HHI 3353
- Roche Diabetes Care GmbH : $52.4K total payments, HHI 3353
- OrganOx Ltd (this company) : $271.0K total payments, HHI 3335
- Midwest Surgical Alliance, LLC : $994.3K total payments, HHI 3333
- Uc-Care (usa), Inc : $12.9K total payments, HHI 3333
- Bioprotect Ltd. : $12.0K total payments, HHI 3333
- Cardinal Health 414 LLC : $311.8K total payments, HHI 3320
- Ortho Organizers, Inc. : $318.5K total payments, HHI 3318
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as OrganOx Ltd's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about OrganOx Ltd.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with OrganOx Ltd.
Showing 6 of 1,924 companies with CMS-reported payment data.
Vascular Technology, Inc.
$943.2K 50 recipients
Compare payment profiles
Almirall LLC
$946.1K 5,128 recipients
Compare payment profiles
Leica Microsystems Inc.
$942.6K 487 recipients
Compare payment profiles
NS Pharma, Inc.
$942.1K 369 recipients
Compare payment profiles
Consortium of Independent Immunology Clinics, LLC
$938.8K 91 recipients
Compare payment profiles
Put this to use
OrganOx Ltd ranks #630 of 1,925 by all-tracks total payments, led by "Grant".
- See where OrganOx Ltd sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Grant" spend across every manufacturer, not just OrganOx Ltd. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.